125 related articles for article (PubMed ID: 32614235)
1. Association of triple positivity with prognostic parameters and overall survival in a population-based study of 6,122 HER2-positive breast cancer patients: analysis of real-world clinical practice based on a research database.
Kolarova I; Vanasek J; Dolezel M; Stuk J; Hlavka A; Dusek L; Melichar B; Büchler T; Ryska A; Prausova J; Petrakova K; Tesarova P; Petera J; Vosmik M; Horackova K; Jarkovsky J
Neoplasma; 2020 Nov; 67(6):1373-1383. PubMed ID: 32614235
[TBL] [Abstract][Full Text] [Related]
2. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
3. Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy.
Chen H; Gui X; Zhou Z; Su F; Gong C; Li S; Wu W; Rao N; Liu Q; Yao H
Breast; 2024 Jun; 75():103733. PubMed ID: 38615482
[TBL] [Abstract][Full Text] [Related]
4. Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer.
Zhao S; Liu XY; Jin X; Ma D; Xiao Y; Shao ZM; Jiang YZ
Theranostics; 2019; 9(17):4935-4945. PubMed ID: 31410192
[No Abstract] [Full Text] [Related]
5. Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea.
Park YH; Karantza V; Calhoun SR; Park S; Lee S; Kim JY; Yu JH; Kim SW; Lee JE; Nam SJ; Aktan G; Marsico M
Breast Cancer Res Treat; 2021 Oct; 189(3):653-663. PubMed ID: 34487293
[TBL] [Abstract][Full Text] [Related]
6. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
7. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.
Shen Q; Sahin AA; Hess KR; Suki D; Aldape KD; Sawaya R; Ibrahim NK
Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of Tumor Subtypes in Women With Breast Cancer According to Stage: A Population-based Study.
Leone JP; Leone J; Zwenger AO; Vallejo CT; Leone BA
Am J Clin Oncol; 2019 Jul; 42(7):588-595. PubMed ID: 31166208
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
[TBL] [Abstract][Full Text] [Related]
11. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
12. African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages.
Arciero CA; Yang J; Peng L; Ward KC; O'Regan R; Sahin AA; Li X
Breast Cancer Res Treat; 2017 Dec; 166(3):743-755. PubMed ID: 28856481
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.
Tas F
Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972
[TBL] [Abstract][Full Text] [Related]
14. Impact of Hormone Receptor Status on the Behaviour of HER2+ Breast Cancer.
Kolarova I; Dusek L; Ryska A; Odrazka K; Dolezel M; Vanasek J; Melichar B; Petera J; Buchler T; Vosmik M; Petrakova K; Terarova P; Vilasova Z; Jarkovsky J
In Vivo; 2020; 34(6):3441-3449. PubMed ID: 33144452
[TBL] [Abstract][Full Text] [Related]
15. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
[TBL] [Abstract][Full Text] [Related]
16. Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material.
Berghuis AMS; van Deurzen CHM; Koffijberg H; Terstappen LWMM; Sleijfer S; IJzerman MJ
Breast Cancer Res Treat; 2019 Jun; 175(2):451-458. PubMed ID: 30756285
[TBL] [Abstract][Full Text] [Related]
17. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Pizzuti L; Krasniqi E; Barchiesi G; Della Giulia M; Izzo F; Sanguineti G; Marchetti P; Mazzotta M; Giusti R; Botticelli A; Gamucci T; Natoli C; Grassadonia A; Tinari N; Iezzi L; Tomao S; Tomao F; Tonini G; Santini D; Astone A; Michelotti A; De Angelis C; Mentuccia L; Vaccaro A; Magnolfi E; Gelibter A; Magri V; Cortesi E; D'Onofrio L; Cassano A; Rossi E; Cazzaniga M; Moscetti L; Omarini C; Piacentini F; Fabbri MA; Scinto AF; Corsi D; Carbognin L; Bria E; La Verde N; Samaritani R; Garufi C; Barni S; Mirabelli R; Sarmiento R; Veltri EM; D'Auria G; Paris I; Giotta F; Lorusso V; Cardillo F; Landucci E; Mauri M; Ficorella C; Roselli M; Adamo V; Ricciardi GRR; Russo A; Berardi R; Pistelli M; Fiorio E; Cannita K; Sini V; D'Ostilio N; Foglietta J; Greco F; Zamagni C; Garrone O; Di Cocco B; Baldini E; Livi L; Desideri I; Meattini I; Sarobba G; Del Medico P; De Tursi M; Generali D; De Maria R; Risi E; Ciliberto G; Sperduti I; Villa A; Barba M; Di Leo A; Vici P
Int J Cancer; 2020 Apr; 146(7):1917-1929. PubMed ID: 31330065
[TBL] [Abstract][Full Text] [Related]
18. Effect of level of hormone-receptor expression on treatment outcomes of "triple-positive" early-stage breast cancer.
Abdel-Razeq H; Edaily S; Iweir S; Salam M; Saleh Y; Sughayer M; Salama O; Mustafa R; Al-Masri Y; Bater R; Taqash A
Breast Cancer Res Treat; 2021 Jan; 185(2):459-467. PubMed ID: 32974788
[TBL] [Abstract][Full Text] [Related]
19. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]